The price cut came as CMS begins to weight whether Medicare should cover Biogen's controversial Alzheimer's disease drug.
Biogen announced on Monday that it was cutting the price of Aduhelm (aducanumab) in half, from an annual cost of $56,000 to $28,200. Here are five things you should know about the drug and the company’s decisions:
Biogen said it is launching a trial of Aduhelm in May that will enroll 1,300 people with early Alzheimer’s, Stat reported last week. When the FDA approved Aduhelm in June, the agency made the approval contingent upon a confirmatory trial verifying its effectiveness.
More than a dozen prominent Alzheimer’s experts and other well-regarded healthcare professional issued a statement on Monday calling on the FDA to withdraw its approval of Aduhelm. Meanwhile, a group called the Right Care Alliance says it is planning to file a citizen’s petition with the agency to ask that Aduhelm be taken off the market.
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen
2024 Emerging Leaders in Healthcare — Submit For a Chance to Be Featured in MHE's August Issue
April 24th 2024MHE Editors are seeking diverse healthcare professionals from different backgrounds and healthcare sectors, with individual interests. Eligible candidates are early or mid-career leaders with less than 10 years of experience. Award winners will enjoy complimentary passes to the PBMI Annual National Meeting in Orlando, Florida, from Sept. 4-6. Additional perks include a feature in our August issue, a subscription to MHE and more!
Read More